In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

Desmond Kwok Po Hau, Guo Yuan Zhu, Alexander Kai Man Leung, Raymond Siu Ming Wong, Gregory Yin Ming Cheng, Paul Bo San Lai, Sze Wai Tong, Fung Yi Lau, Kit Wah Chan, Wai Yeung Wong, Kim Hung Lam, Chor Hing Cheng, Filly Cheung, Chung Hin Chui, Roberto Gambari, David Wang Fun Fong

Research output: Journal article publicationJournal articleAcademic researchpeer-review

47 Citations (Scopus)


We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15. mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma.
Original languageEnglish
Pages (from-to)11-15
Number of pages5
Issue number1
Publication statusPublished - 15 Dec 2010


  • Corilagin
  • Hepatocellular carcinoma
  • Xenograft model

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine


Dive into the research topics of 'In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this